Informational only — Not medical advice. Always consult a licensed healthcare provider.

Community data Updated 2 months ago

Save on this medicine

Other brands with the same active ingredient

These brands contain the same active ingredient (Ivabradine). Same strength and form. Confirm the switch with your doctor or pharmacist.

Indications & Uses

Delpino Tablet 5 mg is indicated for:

Pharmacology

Ivabradine is a pure heart rate lowering agent. It works by selectively and specifically inhibiting the cardiac pacemaker If current, which controls the spontaneous diastolic depolarization in the sinus node and regulates heart rate. By slowing the heart rate, Ivabradine reduces the cardiac workload and, in turn, oxygen consumption. At the same time, it prolongs diastole, allowing greater perfusion of the coronary arteries and increased oxygen supply to the heart. Its cardiac effects are specific to the sinus node, with no effect on intra atrial, atrioventricular or intraventricular conduction times, nor on myocardial contractility or ventricular repolarization.

Dosage Reference

Reference Information Only

Dosages shown are general references from official sources. Always consult your doctor or pharmacist for personalized dosing.

Adults:

Adults: The usual recommended starting dose of ivabradine is 5 mg twice daily. After 3 to 4 weeks of treatment, this may be increased to 7.5 mg twice daily, depending on the response to therapy. The usual dose is 1 tablet in the morning and 1 tablet in the evening, taken with meals. If the resting heart rate falls persistently below 50 bpm, or if symptoms related to a slow heart rate (bradycardia) occur, the dose must be reduced to 2.5 mg twice daily (one half of the 5 mg tablet twice daily). Treatment must be stopped if the heart rate remains below 50 bpm or if symptoms of bradycardia persist.

Elderly: Because ivabradine has been studied in only a limited number of patients aged 75 years or older, a lower starting dose should be considered for these patients (2.5 mg twice daily, that is, one half of a 5 mg tablet twice daily) before increasing the dose if needed.

Renal insufficiency: No dose adjustment is needed in patients with renal insufficiency whose creatinine clearance is above 15 ml/min. No data are available for patients with a creatinine clearance below 15 ml/min, so ivabradine should be used with caution in this group.

Hepatic impairment: No dose adjustment is needed in patients with mild hepatic impairment. Caution should be used when giving ivabradine to patients with moderate hepatic impairment. Ivabradine is contraindicated in patients with severe hepatic insufficiency.

Children and adolescents: Ivabradine is not recommended for children and adolescents because there is a lack of data on its safety and efficacy in this age group.

Side Effects

Visual symptoms, blurred vision, slow heart rate, 1st degree AV block, ventricular extrasystoles, headache, and dizziness.

Cautions & Contraindications

Warnings & Precautions

Ivabradine should be used with caution in people with mild to moderate low blood pressure (hypotension), atrial fibrillation, congenital QT syndrome, or who are taking medicines that prolong the QT interval, as well as in those with moderate liver impairment or severe kidney impairment.

Contraindications

Do not use Ivabradine if you have ever had an allergic reaction to it or to any of its excipients. It should also not be taken if your resting heart rate is below 60 bpm before treatment starts, or if you have cardiogenic shock, an acute myocardial infarction, or severe hypotension (below 90/50 mmHg). People with severe hepatic insufficiency, sick sinus syndrome, sino-atrial block, heart failure, or unstable angina should avoid it too, as should those who depend on a pacemaker or have 3rd degree AV block. Ivabradine must not be combined with strong cytochrome P-450 3A4 inhibitors such as azole antifungals, macrolide antibiotics, or HIV protease inhibitors.

Pregnancy & Breastfeeding

Studies in rats found no effect on fertility in either males or females. Data on the use of ivabradine in pregnant women are either absent or very limited. For that reason, ivabradine should not be used during pregnancy. Animal studies also show that ivabradine passes into breast milk, so it should not be used while breastfeeding.

⚠️ Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.

Storage

Store Ivabradine below 30°C, and keep it away from light and moisture. Keep it out of the reach of children.

Drug Interactions

Open checker →
Moderate Erythromycin
Moderate Mefloquine
Moderate Disopyramide
Moderate Ziprasidone

Common questions about Delpino Tablet 5 mg 5 mg

What is Delpino Tablet 5 mg 5 mg Tablet?

Delpino Tablet 5 mg 5 mg Tablet is a medicine that contains Ivabradine. It is made by Healthcare Pharmaceuticals Ltd. It belongs to the Other Anti-anginal & Anti-ischaemic drugs group of medicines.

What is Delpino Tablet 5 mg used for?

Delpino Tablet 5 mg is used for: Angina Pectoris.

What are the side effects of Delpino Tablet 5 mg?

Visual symptoms, blurred vision, slow heart rate, 1st degree AV block, ventricular extrasystoles, headache, and dizziness.

Can I take Delpino Tablet 5 mg during pregnancy or while breastfeeding?

Studies in rats found no effect on fertility in either males or females. Data on the use of ivabradine in pregnant women are either absent or very limited. Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.

How should I store Delpino Tablet 5 mg?

Store Ivabradine below 30°C, and keep it away from light and moisture. Keep it out of the reach of children.

Can I take other medicines with Delpino Tablet 5 mg?

Some medicines can interact with Ivabradine, for example: Erythromycin, Mefloquine, Disopyramide, Ziprasidone, Amiodarone Hydrochloride, Sotalol Hydrochloride. Tell your doctor or pharmacist about every medicine you take.

Do I need a prescription for Delpino Tablet 5 mg?

Delpino Tablet 5 mg is a prescription (Rx) medicine. Take it as your doctor advises.

Last updated: 15 Aug 2026